Estados financieros detallados de PMV Pharmaceuticals, Inc. (PMVP): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.43, PMVP presenta beneficios negativos (P/E no significativo) y un ROE del -78.11%. La capitalización bursátil es de $76M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $338000 | $388000 | $318000 | $1.3M | $650000 | $1.3M | $1.1M | 0 |
| Beneficio Bruto | -$338000 | -$388000 | -$318000 | -$1.3M | -$650000 | -$1.3M | -$1.1M | 0 |
| I+D | $13.9M | $20.8M | $23.6M | $36.2M | $51.7M | $54.6M | $57.4M | $69.9M |
| Generales y Administrativos | $5.0M | $5.5M | $11.0M | $20.8M | $24.7M | $24.2M | $26.9M | $16.3M |
| Gastos Operativos | $18.9M | $26.2M | $34.6M | $57.0M | $76.4M | $78.9M | $84.3M | $86.2M |
| Beneficio Operativo | -$18.9M | -$26.6M | -$34.9M | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M |
| EBITDA | -$18.6M | -$25.0M | -$34.1M | -$56.5M | -$72.7M | -$67.7M | -$73.7M | -$79.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$17.5M | -$25.3M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$74.8M | -$79.9M |
| Impuestos | $3000 | $8000 | $6000 | $23000 | -$9000 | $2000 | -$16.1M | -$2.2M |
| Beneficio Neto | -$17.5M | -$25.4M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M |
| BPA | $-5.80 | $-0.59 | $-2.40 | $-1.28 | $-1.61 | $-1.44 | $-1.14 | $-1.48 |
| BPA Diluido | $-5.80 | $-0.59 | $-2.40 | $-1.28 | $-1.61 | $-1.44 | $-1.14 | $-1.48 |
| Acciones en Circulación (Diluidas) | $3.0M | $43.0M | $44.8M | $45.1M | $45.6M | $48.0M | $51.6M | $52.5M |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $30.3M | $73.3M | $361.4M | $172.5M | $108.3M | $37.7M | $40.9M | $38.0M |
| Inversiones a Corto | $31.6M | $28.2M | 0 | $124.7M | $132.8M | $165.4M | $128.6M | $75.0M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $62.2M | $102.1M | $364.8M | $301.3M | $247.0M | $207.4M | $175.7M | $115.2M |
| Inmovilizado Material | $1.0M | $739000 | $569000 | $13.2M | $20.5M | $19.0M | $1.6M | $1.0M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $63.5M | $103.0M | $365.5M | $331.6M | $270.3M | $252.2M | $191.3M | $116.6M |
| Cuentas por Pagar | $1.0M | $2.8M | $1.6M | $3.2M | $3.0M | $3.2M | $6.6M | $3.2M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | $352000 | 0 |
| Pasivos Corrientes | $2.3M | $4.5M | $6.4M | $12.2M | $10.8M | $14.0M | $14.4M | $11.4M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $435000 |
| Pasivos Totales | $109.6M | $173.5M | $6.4M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M |
| Reservas | -$50.1M | -$75.4M | -$109.9M | -$167.7M | -$241.0M | -$310.0M | -$368.7M | -$446.5M |
| Patrimonio Neto | -$46.1M | -$70.5M | $359.1M | $308.6M | $246.0M | $225.7M | $176.1M | $104.7M |
| Deuda Total | $107.2M | 0 | 0 | $11.2M | $14.0M | $13.3M | $1.2M | $838000 |
| Deuda Neta | $45.3M | -$101.5M | -$361.4M | -$286.0M | -$227.1M | -$189.8M | -$168.3M | -$112.1M |
| Capital Circulante | $59.9M | $97.6M | $358.4M | $289.1M | $236.2M | $193.4M | $161.3M | $103.8M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$17.5M | -$25.4M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M |
| Amortizaciones | $338000 | $388000 | $318000 | $307000 | $315000 | $1.3M | $1.1M | $133000 |
| Compensación en Acciones | $1.1M | $908000 | $1.9M | $5.3M | $10.2M | $12.4M | $8.9M | $5.9M |
| Cambio en Capital Circulante | $637000 | $1.9M | -$845000 | $4.1M | -$568000 | $5.4M | -$1.6M | $914000 |
| Flujo de Caja Operativo | -$15.2M | -$22.1M | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M |
| Inversiones (CapEx) | -$452000 | -$109000 | -$148000 | -$1.3M | -$8.0M | -$962000 | -$655000 | -$29000 |
| Adquisiciones | 0 | 0 | $148000 | 0 | 0 | 0 | $251000 | $31000 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$15.6M | -$22.2M | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -44.6% | -35.8% | -68.0% | -26.7% | +5.9% | +14.9% | -32.4% | |
| Crecimiento BPA (anual) | +89.8% | -306.8% | +46.7% | -25.8% | +10.6% | +21.0% | -30.0% | |
| Cambio en Acciones (anual) | +1321.9% | +4.1% | +0.8% | +1.0% | +5.3% | +7.4% | +1.9% | |
| Crecimiento FCF (anual) | -41.9% | -48.3% | -45.7% | -49.7% | +21.1% | +8.3% | -41.7% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | -0.0% | 21.5% | 2.7% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-5.17 | $-0.52 | $-0.73 | $-1.06 | $-1.57 | $-1.18 | $-1.01 | $-1.40 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $3.0M | $43.0M | $44.8M | $45.1M | $45.6M | $48.0M | $51.6M | $52.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -78.11% |
| Rentabilidad sobre capital invertido | -111.08% |
| Rentabilidad sobre activos | -91.66% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 7.70 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.41 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -6.47 | -63.58 | -25.63 | -18.05 | -5.40 | -2.15 | -1.33 | -0.84 |
| P/VC | -2.46 | -22.89 | 7.67 | 3.38 | 1.61 | 0.66 | 0.44 | 0.63 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ACRV · ATYR · BMEA · CBUS · IMUX · LITS · RLMD
Explorar sector: Healthcare · Biotechnology
Más secciones de PMVP: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones